2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Breast Neoplasms
2
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Colonic Neoplasms
1
Interventions
Trastuzumab
732
Paclitaxel
695
Cyclophosphamide
647
Docetaxel
560
Capecitabine
486
Letrozole
437
Fulvestrant
400
Carboplatin
398
Doxorubicin
341
Tamoxifen
308
Anastrozole
279
pembrolizumab
274
exemestane
258
Epirubicin
251
pertuzumab
240
Radiotherapy
239
palbociclib
224
Bevacizumab
222
Gemcitabine
215
Vinorelbine
197
Lapatinib
181
130-nm albumin-bound paclitaxel
172
Magnetic Resonance Spectroscopy
164
Albumin-Bound Paclitaxel
157
eribulin
154
Surveys and Questionnaires
152
Exercise
151
Drug Therapy
141
Taxes
134
Fluorouracil
133
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Isoflurane
×
Breast
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled
NCT00575354
2008-04-21
CSIABTEC
Nanjing Medical University
Phase 4
Completed
500 enrolled